@article{oai:niigata-u.repo.nii.ac.jp:00012677,
 author = {加藤, 公則 and 西川, 尚 and 小澤, 拓也 and 真木山, 八城 and 皆川, 史郎 and 相澤, 義房},
 issue = {2},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Feb},
 note = {There are several methods of neovascularization therapy for ischemic heart disease: gene ther-apy with angiogenic factors, cell therapy with endothelial progenitor cells, and cytokine therapy with granulocyte colony stimulating factor(G-CSF). However, from the viewpoint of efficacy and safety, cell therapy is thought to be the best approach for regeneration therapy. There has been some scepticism about the efficacy of gene therapy with a single angiogenic factor because angiogenesis is considered to involve several angiogenic factors. It was initially reported that G-CSF therapy caused a high incidence of myocardial infarction or in-stent coronary artery restenosis. Subsequently, intracoronary infusion or intramyocardial injection of bone marrow mononuclear cells or peripheral blood endothelial progenitor cells was shown to be effective in patients with acute myocardial infarction or in those after myocardial infarction. Recently, we found that erythropoietin enhanced angiogenesis induced by implantation of bone marrow mononuclear cells in a murine model of limb ischemia. With the aim of applying this combination therapy for human ischemic heart disease, we are now investigating its effect on the heart.},
 pages = {83--89},
 title = {5 虚血性心疾患に対する血管新生療法(シンポジウム 心不全治療の最近のトピックス,第600回新潟医学会次第)},
 volume = {119},
 year = {2005}
}